leadership
Executive Team
Leadership Team
Board of Directors
Gustav Christensen, MBA

Chairman

Timothy Springer, PhD

Founder, Morphic Therapeutic

Norbert Bischofberger, PhD

Director

Martin Edwards, MBA

Director

Susannah Gray, MBA

Director

Nisha Nanda, PhD

Director

Amir Nashat, MD

Director

Joseph P. Slattery, CPA

Director

Praveen Tipirneni, MD, MBA

Director

Clinical Advisory Board
Silvio Danese, MD, PhD
Brian G. Feagan, MD, FRCPC
Laurent Peyrin-Biroulet, MD, PhD
Bruce Sands, MD, MS
Scientific Advisory Board
Timothy Springer, PhD

Founder, Morphic Therapeutic

Ulrich Von Andrian, MD, PhD
Albert Robichaud, PhD
Shelia Violette, PhD
Scott L. Friedman, MD
Yury Popov, MD, PhD
Miriam Merad, MD, PhD
Scroll to Top

Contact Us

Integrin Partnership: Janssen

Morphic entered a research partnership with Janssen in 2019 to discover inhibitors of undisclosed integrin targets. In 2021, this partnership was expanded to include an antibody activator of an integrin target, extending the application of Morphic’s knowledge of integrin biology into modalities beyond small molecules. The antibody activator program is the focus of our collaboration with Janssen today.

Undisclosed Targets

Morphic is leveraging the MInT Platform to discover therapeutically relevant small molecule inhibitors of targets across the integrin family to treat autoimmune diseases, cancer and fibrotic diseases.

Undisclosed Target for Pulmonary Arterial Hypertension

Morphic is deploying the MInT Platform to create small molecule inhibitors of an undisclosed integrin target for evaluation as a potential treatment for pulmonary arterial hypertension (PAH). PAH is a devastating, usually fatal disease characterized by elevated mean pressures in the pulmonary artery and associated with lung and heart dysfunction. Morphic’s PAH program is in preclinical development.

αvβ8

Morphic is developing small molecule inhibitors of the integrin αvβ8 through a combination immuno-oncology approach for the treatment of solid tumors as well as potential additional indications. αvβ8 is known to activate selective isoforms of TGF-β and Morphic has demonstrated that αvβ8 inhibition can potentiate immune checkpoint blockade and potentially drive responses in checkpoint refractory tumors. Morphic’s αvβ8 inhibitors are in preclinical development.

Next Gen α4β7 Inhibitors

Morphic is developing a family of next generation α4β7 small molecule inhibitors with enhanced attributes using the MInT Platform. These candidates have distinct chemical properties from our first-generation inhibitors with differentiated selectivity, potency, and pharmacokinetic profiles. Morphic’s next generation α4β7 inhibitors are currently in preclinical development.